Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company is advancing a product candidate targeting conditions related to pulmonary indications. Savara is conducting clinical trials and pursuing regulatory approval for its pipeline. The company has no currently approved products and relies on third-party manufacturers and clinical research organizations to support its development activities.
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001193125-26-105076 | EDGAR | 69K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-045731 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0000950170-24-027920 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010967 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0000950170-22-005045 | EDGAR | — |
| 2021-03-10 | 2020-12-31 | 0001564590-21-011919 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010465 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007585 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001564590-18-005610 | EDGAR | — |
| 2017-03-06 | 2016-12-31 | 0001564590-17-003487 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-344585 | EDGAR | — |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277525 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107631 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070283 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125292 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095403 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056954 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062040 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041323 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021981 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024458 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016860 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001193125-26-105099 | EDGAR | 24K words |
| 2026-01-27 | 0001193125-26-023378 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008301 | EDGAR | — |
| 2025-10-30 | 0001193125-25-258629 | EDGAR | — |
| 2025-10-29 | 0001193125-25-256290 | EDGAR | — |
| 2025-09-02 | 0001193125-25-193507 | EDGAR | — |
| 2025-06-06 | 0001193125-25-137150 | EDGAR | — |
| 2025-05-27 | 0001193125-25-126273 | EDGAR | — |
| 2025-03-31 | 0001193125-25-067658 | EDGAR | — |
| 2025-03-26 | 0001193125-25-064145 | EDGAR | — |
413 total filings indexed. 381 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001160308 |
| Ticker | SVRA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.savarapharma.com |
| Listed | 1996-11-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SVRA (~200 tokens, structured JSON with cryptographic provenance)